Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants

Prajwal Dhakal, Supratik Rayamajhi, Vivek Verma, Krishna Gundabolu, Vijaya R Bhatt

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Bleeding is the most common complication of all anticoagulants. Any bleeding patient on an anticoagulant should be risk-stratified based on hemodynamic instability, source of bleeding, and degree of blood loss. Although minor bleed may be managed with discontinuation of anticoagulant, major bleed may require transfusion of blood products and use of specific antidote. The residual effects of each anticoagulant may be monitored with distinct coagulation assay. Intravenous or oral vitamin K can reverse the effect of warfarin within 24 to 48 hours and is indicated for any bleeding, international normalized ratio of >10 or 4.5 to 10 in patients with other risk factors for bleeding. Fresh frozen plasma or prothrombin complex concentrate (PCC) may be necessary in major bleeding related to warfarin. Protamine sulfate reverses the effect of unfractionated heparin completely and of low-molecular-weight heparin (LMWH) partially. Idarucizumab has recently been approved in United States for dabigatran reversal, whereas andexanet alfa is expected to get approved in the near future for reversal of oral factor Xa inhibitors. The PCC may reverse the effect of rivaroxaban to some extent, but no data are available regarding reversal of apixaban and edoxaban. Aripazine has shown promising results to reverse the effects of LMWH, fondaparinux, and direct oral anticoagulants but is still in the developmental phase.

Original languageEnglish (US)
Pages (from-to)410-415
Number of pages6
JournalClinical and Applied Thrombosis/Hemostasis
Volume23
Issue number5
DOIs
StatePublished - Jul 1 2017

Fingerprint

Anticoagulants
Hemorrhage
Low Molecular Weight Heparin
Warfarin
Antidotes
Protamines
International Normalized Ratio
Vitamin K
Blood Transfusion
Heparin
Hemodynamics
prothrombin complex concentrates

Keywords

  • anticoagulants
  • antidote
  • bleeding
  • reversal

ASJC Scopus subject areas

  • Hematology

Cite this

Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants. / Dhakal, Prajwal; Rayamajhi, Supratik; Verma, Vivek; Gundabolu, Krishna; Bhatt, Vijaya R.

In: Clinical and Applied Thrombosis/Hemostasis, Vol. 23, No. 5, 01.07.2017, p. 410-415.

Research output: Contribution to journalReview article

@article{1515510d3e0243aea5e4ed333f5547af,
title = "Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants",
abstract = "Bleeding is the most common complication of all anticoagulants. Any bleeding patient on an anticoagulant should be risk-stratified based on hemodynamic instability, source of bleeding, and degree of blood loss. Although minor bleed may be managed with discontinuation of anticoagulant, major bleed may require transfusion of blood products and use of specific antidote. The residual effects of each anticoagulant may be monitored with distinct coagulation assay. Intravenous or oral vitamin K can reverse the effect of warfarin within 24 to 48 hours and is indicated for any bleeding, international normalized ratio of >10 or 4.5 to 10 in patients with other risk factors for bleeding. Fresh frozen plasma or prothrombin complex concentrate (PCC) may be necessary in major bleeding related to warfarin. Protamine sulfate reverses the effect of unfractionated heparin completely and of low-molecular-weight heparin (LMWH) partially. Idarucizumab has recently been approved in United States for dabigatran reversal, whereas andexanet alfa is expected to get approved in the near future for reversal of oral factor Xa inhibitors. The PCC may reverse the effect of rivaroxaban to some extent, but no data are available regarding reversal of apixaban and edoxaban. Aripazine has shown promising results to reverse the effects of LMWH, fondaparinux, and direct oral anticoagulants but is still in the developmental phase.",
keywords = "anticoagulants, antidote, bleeding, reversal",
author = "Prajwal Dhakal and Supratik Rayamajhi and Vivek Verma and Krishna Gundabolu and Bhatt, {Vijaya R}",
year = "2017",
month = "7",
day = "1",
doi = "10.1177/1076029616675970",
language = "English (US)",
volume = "23",
pages = "410--415",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants

AU - Dhakal, Prajwal

AU - Rayamajhi, Supratik

AU - Verma, Vivek

AU - Gundabolu, Krishna

AU - Bhatt, Vijaya R

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Bleeding is the most common complication of all anticoagulants. Any bleeding patient on an anticoagulant should be risk-stratified based on hemodynamic instability, source of bleeding, and degree of blood loss. Although minor bleed may be managed with discontinuation of anticoagulant, major bleed may require transfusion of blood products and use of specific antidote. The residual effects of each anticoagulant may be monitored with distinct coagulation assay. Intravenous or oral vitamin K can reverse the effect of warfarin within 24 to 48 hours and is indicated for any bleeding, international normalized ratio of >10 or 4.5 to 10 in patients with other risk factors for bleeding. Fresh frozen plasma or prothrombin complex concentrate (PCC) may be necessary in major bleeding related to warfarin. Protamine sulfate reverses the effect of unfractionated heparin completely and of low-molecular-weight heparin (LMWH) partially. Idarucizumab has recently been approved in United States for dabigatran reversal, whereas andexanet alfa is expected to get approved in the near future for reversal of oral factor Xa inhibitors. The PCC may reverse the effect of rivaroxaban to some extent, but no data are available regarding reversal of apixaban and edoxaban. Aripazine has shown promising results to reverse the effects of LMWH, fondaparinux, and direct oral anticoagulants but is still in the developmental phase.

AB - Bleeding is the most common complication of all anticoagulants. Any bleeding patient on an anticoagulant should be risk-stratified based on hemodynamic instability, source of bleeding, and degree of blood loss. Although minor bleed may be managed with discontinuation of anticoagulant, major bleed may require transfusion of blood products and use of specific antidote. The residual effects of each anticoagulant may be monitored with distinct coagulation assay. Intravenous or oral vitamin K can reverse the effect of warfarin within 24 to 48 hours and is indicated for any bleeding, international normalized ratio of >10 or 4.5 to 10 in patients with other risk factors for bleeding. Fresh frozen plasma or prothrombin complex concentrate (PCC) may be necessary in major bleeding related to warfarin. Protamine sulfate reverses the effect of unfractionated heparin completely and of low-molecular-weight heparin (LMWH) partially. Idarucizumab has recently been approved in United States for dabigatran reversal, whereas andexanet alfa is expected to get approved in the near future for reversal of oral factor Xa inhibitors. The PCC may reverse the effect of rivaroxaban to some extent, but no data are available regarding reversal of apixaban and edoxaban. Aripazine has shown promising results to reverse the effects of LMWH, fondaparinux, and direct oral anticoagulants but is still in the developmental phase.

KW - anticoagulants

KW - antidote

KW - bleeding

KW - reversal

UR - http://www.scopus.com/inward/record.url?scp=85020425492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020425492&partnerID=8YFLogxK

U2 - 10.1177/1076029616675970

DO - 10.1177/1076029616675970

M3 - Review article

C2 - 27789605

AN - SCOPUS:85020425492

VL - 23

SP - 410

EP - 415

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 5

ER -